Field trials have resulted in significant
improvement, while leaving minimal footprint
ICL (NYSE: ICL) (TASE: ICL), a leading global specialty
minerals company, and ag-biotech company PlantArcBio, Ltd.
(TASE: PLNT), today announced the development of a novel
bio-stimulant technology platform, which will improve crop yields
while having a minimal impact on the environment. The platform
successfully uses of RNAi technology to maximize a plant's natural
yield increase mechanisms, without any genetic modification, and
was the result of a multi-year research collaboration between the
two companies.
In early-stage canola field trials, the platform has
significantly increased seed weight per hectare for canola crops,
and ICL and PlantArcBio are planning larger-scale field trials in
2022. These will include testing the new technology platform using
both commercial sprayers and standard farming practices. Greenhouse
trials for soybeans and rice are already in progress, with early
results showing good potential.
"The use of novel biostimulants based on RNAi technology helps
promote sustainability, by reducing the use of chemicals in
agriculture," explained Hadar Sutovsky, vice president of External
Innovation and general manager of ICL Planet. "This aligns
perfectly with ICL's long-term goal of creating impact and
sustainable growth in the agriculture end-market, alongside
ensuring food security." The global biostimulants market was
estimated to be $3.2 billion in 2021 and is projected to grow at a
CAGR of 12.1% to reach $5.6 billion by 2026, according to
ReportLinker.com.
"ICL and PlantArcBio have filed for a joint patent on the
application for multiple crops," said Sutovsky. "The application
does its work, then rapidly disappears from both the plants and the
environment, lasting no more than a few days, as it is highly
biodegradable and also leaves no residual footprint."
"The positive canola field trial results constitute another
milestone in strengthening PlantArcBio's capabilities in the
development of RNAi-based products," said Dror Shalitin, Ph.D.,
founder and CEO of PlantArcBio. "ICL, a market leader in crop
nutrition products, is a great strategic partner for us to
commercialize this sustainable technology worldwide."
About ICL
ICL Group is a leading global specialty minerals company, which
also benefits from commodity upside. The company creates impactful
solutions for humanity's sustainability challenges in the global
food, agriculture and industrial markets. ICL leverages its unique
bromine, potash and phosphate resources, its passionate team of
talented employees, and its strong focus on R&D and
technological innovation, to drive growth across its end markets.
ICL shares are dually listed on the New York Stock Exchange and the
Tel Aviv Stock Exchange (NYSE and TASE: ICL). The company employs
more than 12,000 people worldwide, and its 2021 revenues totaled
approximately $7 billion.
For more information, visit ICL's website at www.icl-group.com.
To access ICL's interactive ESG report, please click here. You can
also learn more about ICL on Facebook, LinkedIn and Instagram.
About PlantArcBio
PlantArcBio, Ltd. (PAB) is a public Ag-biotech company [TASE:
PLNT], with an innovative and IP protected Direct-In-Plant (DIP™)
discovery platform, intended primarily for use in the agricultural
industry, with a vision to contribute to global food security and
address sustainable agriculture. With its platform, the company
discovers and develops novel genes and biological components that
have beneficial effects on plants, such as yield improvement,
drought resistance, and herbicide and insect tolerance.
For more information, visit PlantArcBio’s website at
www.plantarcbio.com or contact Dr. Dror Shalitin, founder and CEO,
at dror@plantarcbio.com or by phone at +972-50-3161062.
Forward Looking Statements
This announcement contains statements that constitute
forward‑looking statements, many of which can be identified by the
use of forward‑looking words such as “estimate,” “anticipate,”
“believe,” “could,” “expect,” “should,” “plan,” “intend,” and
“potential,” among others.
Forward-looking statements appear in this press release and
include, but are not limited to, statements regarding the company’s
intent, belief or current expectations. Forward-looking statements
are based on management’s beliefs and assumptions and on
information currently available to management. Such statements are
subject to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including, but not limited to:
estimates, forecasts and statements as to management's expectations
with respect to, among other things, business and financial
prospects, financial multiples and accretion estimates, future
trends, plans, strategies, positioning, objectives and
expectations, general economic, market and business conditions,
supply chain and logistics disruptions, energy storage and electric
vehicle growth, the potential for new COVID-19 variants, global
unrest and conflict, governmental and regulatory requirements and
actions by governmental authorities, including changes in
government policy, changes in environmental, tax and other laws or
regulations and the interpretation thereof. As a result of the
foregoing, readers should not place undue reliance on the
forward‐looking statements contained in this press release
concerning the timing of the transaction, or other more specific
risks and uncertainties facing ICL, such as those set forth in the
“Risk Factors” section of its Annual Report on Form 20-F filed on
February 23, 2022, as such risk factors may be updated from time to
time in its Current Reports on Form 6-K and other filings ICL makes
with the U.S. Securities and Exchange Commission from time to
time.
Forward-looking statements refer only to the date they are made,
and the company does not undertake any obligation to update them in
light of new information or future developments or to publicly
release any revisions to these statements in order to reflect later
events or circumstances or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220719005758/en/
Investor Relations Contact Peggy Reilly Tharp VP, Global
Investor Relations +1-314-983-7665
Peggy.ReillyTharp@icl-group.com
Press Contact Liat Simha NutriPR +972-9-974-2893
liat@nutripr.com
ICL (NYSE:ICL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
ICL (NYSE:ICL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024